VentriPoint VMS(TM) Heart Analysis System Installed at Allegheny General Hospital in Pittsburgh
MAY 11, 2012 - 07:00 ET
FOR: VENTRIPOINT DIAGNOSTICS LTD.
-First Patient Completed in In Support of Pulmonary Arterial Hypertension Clinical Trial-
SEATTLE, WASHINGTON--(Marketwire - May 11, 2012) - VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT) (OTCQX:VPTDF) has installed its latest version of the VMS™ heart analysis system at Allegheny General Hospital in Pittsburgh to support its clinical trials program and for other research purposes. The first Pulmonary Arterial Hypertension (PAH) patient has completed the MRI and VMS™ scans.
The VMS™ heart analysis system works with all existing 2D cardiac ultrasound machines to obtain 3D functional information in 15 minutes. The heart information is identical to the same information obtained in an MRI, which takes over an hour. This revolutionary approach has been publish in major medical journals in 2010 and 2011 and is now in routine clinical use in Europe and Canada.
"This technology has the potential to transform the assessment of patients with PAH. It combines the speed and ease of echocardiography with 3 dimensional quantitative assessment of the heart's right ventricular structure and function, a capability previously available only with MRI", said Dr. Amresh Raina, Heart Failure/Transplant & Pulmonary Hypertension, Allegheny General Hospital and Assistant Professor of Medicine, Temple University School of Medicine.
PAH, the most serious form of the five recognized groups of pulmonary hypertension, is a devastating disease with an average patient lifespan of less than 3 years after diagnosis if untreated. It affects individuals from infancy to the elderly. It is widely known that PAH patients treated early after detection have better results than patients that start later. As it stands, the majority of patients with PAH continue to be diagnosed too late for treatment to be fully effective. PAH can occur for no known reason but will typically occur in association with many common conditions such as chronic liver disease and liver cirrhosis; connective tissue disorders such as scleroderma or systemic lupus erythematosus (lupus); congenital heart disease (even if repaired) and HIV. With increasing availability of effective therapies, and evidence-based treatment guidelines recommending starting treatment early, tests enabling detection as early as possible should prove invaluable.
"Allegheny is a major centre for treating pulmonary hypertension and so with our success in validating the Pulmonary Arterial Hypertension application, said Dr. George Adams, CEO of VentriPoint. "We are expecting to have all the data we require for submission to the FDA in Q3 of this year.
The VMS™ is for investigational use only in the United States and is approved for sale and clinical use in Canada and Europe.
About Allegheny General Hospital
At Allegheny General Hospital is a national leader in cardiovascular, cancer, neuroscience and orthopaedic and rehabilitation care and offers a wide array of medical and surgical specialties. Annually, it admits more than 29,000 patients; log over 68,000 emergency visits; and perform more than 21,000 surgical procedures.
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. Management believes the VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure, which management believes has a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ heart analysis system and VentriPoint is pursuing the US-FDA approval through the 510(k) process.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. These forward-looking statements are made as of the date of this press release and, other than as required by applicable securities laws, the Corporation does not assume any obligation to update or revise them to reflect new events or circumstances. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
VentriPoint Diagnostics Ltd.
Dr. George Adams
(206) 283-0221, ext. 401
Howard Group Inc.
1.888-221-0915 or 403-221-0915
Allegheny General Hospital
Director, System Media Relations